top of page

Reading Radioligand Binding in Human Brain Tissue: When adjacent sections aren't enough

11 minutes ago
3 min read

What two published tracer studies show about where a ligand binds, and what in vitro evidence can and cannot support

Contributing Author Dan Sunnemark, Offspring Biosciences
The cover page of Offspring Biosciences latest white paper: Seeing the Bond, How Receptor Autoradiography Characterizes Ligand Binding in Human Disease Tissue.  Background shows ARG performed in conjuction with histological staining n the same tissue.

A candidate PET ligand for α-synuclein was screened on recombinant fibrils and gave a Ki of 22.5 nM, with roughly 60-fold weaker affinity for tau and Aβ in Alzheimer homogenate. In human brain tissue sections the picture changed. Target binding was limited in Parkinson's disease and multiple system atrophy, and showed the strongest binding in PSP and CBD, where the signal corresponded spatially to 4-repeat tauopathies. Affinity measured in a tube did not predict what the ligand does in diseased tissue. That is why where the binding falls matters as much as how strongly the ligand binds.



What adjacent sections tell you

The routine approach pairs autoradiography on one section with IHC for the relevant pathology on the next, and aligns the images using shared landmarks such as vessels and tissue boundaries. For regional, laminar or lesion-level questions this is sufficient. Its limit is structural: adjacent sections are never identical, so fine-scale correspondence is approximate and cell-level correspondence cannot be assumed. In the α-synuclein study, consecutive-section IHC and emulsion autoradiography on tissue microarrays showed signal at α-synuclein inclusions in PD and MSA, at dense Aβ deposits in cerebral amyloid angiopathy, and at 4-repeat tauopathies in PSP and CBD. That cross-pathology picture is what a program needs before deciding on a candidate.


An infographic describing the process of characterizing ligand binding in human disease tissue in three steps: 1. Ligand & Assay design.  2, Human Disease Tissue Pathology. 3. Binding and Pathology Readouts.

When the question needs the same section

Some questions depend on structures that sit next to each other. In Alzheimer's disease, neuritic plaques are extracellular Aβ deposits surrounded by dystrophic neurites that contain pTau. Phospho-Tau tracers also have a documented record of off-target binding, for example to neuromelanin-containing cells, MAO and meninges . Two slides can show that signal lies near a lesion. They cannot show which component the ligand follows.


Running autoradiography and IHC on the same physical section removes the mismatch between the two readouts. Radiosensitive nuclear emulsion is coated over the section, and silver grains from a tritiated ligand are read against the stained pathology at cellular level. Phosphor imaging stays in the workflow, because it gives the calibrated regional binding parameters. The emulsion adds the localization.


An example: [3H]OXD-2314 in 4-repeat tauopathies tissue

[18F]OXD-2314 was designed as a PET tracer for pTau aggregates in non-Alzheimer's tauopathies. Homogenate assays showed high affinity, but not where the ligand binds. We analyzed FFPE brain sections from PSP, CBD, AD and control cases with 3 nM [3H]OXD-2314, and in PSP and CBD cases combined AT8 staining with emulsion autoradiography on the same section. In CBD cortex, silver grains lay over AT8-positive structures, and excess unlabeled OXD-2314 markedly reduced them on an adjacent section. The overlay is visual and qualitative, and it supports tau-associated binding in this tissue.



What this evidence does not establish

Same-section analysis removes one source of uncertainty, not all of them. Emission range and grain dispersion limit resolution, antibody validity matters, and the IHC conditions must not abolish the ligand's binding site. The data are in vitro evidence for where a ligand binds relative to a competitor. Exposure, blood-brain barrier passage and in vivo occupancy need other methods, and molecular contact is a separate question that isPLA addresses.


Three questions to ask any provider:


  • Which section was the signal read on, the same section as the stain or an adjacent one, and at what resolution?

  • What defines non-specific binding: which competitor, at what concentration, on which section?

  • How was ligand binding checked after the IHC steps?




Read more . . .


The displacement and saturation designs, calibration and both case studies are in our technical article, Seeing the Bond: How Receptor Autoradiography Characterizes Ligand Binding in Human Disease Tissue: Autoradiography | OffspringBiosciences


To discuss which configuration suits your target and tissue, contact one of our senior scientists: Contact Offspring Biosciences | Discuss Your Pharma Project


References


 
 
Post: Blog2_Post
bottom of page